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Abstract
Background: Methionyl-tRNA synthetase (MRS) plays a critical role in initiating translation by transferring Met to
the initiator tRNA (tRNAi
Met) and protection against ROS-mediated damage, suggesting that its overexpression is
related to cancer growth and drug resistance. In this study, the clinical implication of MRS expression in non-small cell
lung cancer (NSCLC) was evaluated.
Methods: Immunoblot and immunohistochemical (IHC) analyses were performed using tissue lysates and formalin-fixed
paraffin embedded (FFPE) tissue blocks from wild type C57BL/6, LSL-Kras G12D, and LSL-Kras G12D:p53fl/fl mice.
For human studies, 12 paired adjacent normal appearing lung tissue lysates and cancer tissue lysates, in addition
to 231 FFPE tissue samples, were used.
Results: MRS was weakly expressed in the spleen and intestinal epithelium and only marginally expressed in
the kidney, liver, and lungs of wild type C57BL/6 mice. On the other hand, MRS was strongly expressed in
the neoplastic region of lung tissue from LSL-Kras G12D and LSL-Kras G12D:p53fl/fl mice. Immunoblot analysis
of the human normal appearing adjacent and lung cancer paired tissue lysates revealed cancer-specific MRS
overexpression, which was related to mTORC1 activity. IHC analysis of the 231 FFPE lung cancer tissue samples showed
that MRS expression was frequently detected in the cytoplasm of lung cancer cells (179 out of 231, 77.4%), with a small
proportion (73 out of 231, 31.6%) also showing nuclear expression. The proportion of cases with positive MRS expression
was higher in the advanced pStage subgroup (P = 0.018, χ2-test) and cases with MRS expression also had shorter DFS
(161.6 vs 142.3, P = 0.014, log-rank test).
Conclusions: Taken together, MRS is frequently overexpressed in NSCLC. Moreover, MRS is related to mTORC1
activity and its overexpression is associated with poor clinical outcomes, indicating that it has potential as a
putative therapeutic target.
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Background
Lung cancer is a major public health problem world-
wide. This disease has a high prevalence and high mor-
tality; specifically, lung cancer had the 3rd lowest
survival rate among all cancers in 2014 [1, 2]. Thus,
there is an urgent need for new diagnostic methods en-
abling early detection and for new treatment modalities
for lung cancer.
Low-dose computerized tomography (LDCT) scans
are currently used as a screening tool. Their use is sup-
ported by the National Lung Screening Trial (NLST), a
randomized collected study involving more than 53,000
current or former heavy smokers [3]. However, lung can-
cer screening with LDCT has serious problems, such as
false-positive rates exceeding 95%. This drawback leads
to unnecessary repeated testing and increased costs [4].
Because of this and other limitations, new noninvasive
methods for the early detection of lung cancer are
needed. Multiple peripheral blood or body fluid matrix
biomarkers in lung cancer have been proposed, such as
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protein biomolecules, miRNA, cell-free DNA, methy-
lated DNA, circulating tumor cells, metabolites, and
lipids [5]. However, protein markers are the only type of
cancer biomarkers approved by the Food and Drug
Administration (FDA) to date [6]. Protein biomarkers
are easy to detect with high sensitivity and/or specificity
in peripheral blood.
Aminoacyl-tRNA synthetases (ARSs) are housekeeping
enzymes that catalyze the ligation of amino acids to their
cognate transfer RNAs (tRNAs) with high fidelity [7].
Consuming one ATP in each reaction, these enzymes
activate amino acids to aminoacyladenylates and then
deliver the activated amino acids to the acceptor ends of
tRNAs [8]. Mammalian ARSs have additional domains
such as a glutathione S-transferase domain, a WHEP do-
main, leucine zipper domains, and α-helical appendices,
which enable them to perform versatile intracellular and
intercellular functions. Among the free-form ARSs,
tryptophanyl-tRNA synthetase (WRS) and tyrosyl-tRNA
synthetase (YRS) can be secreted and modified to con-
trol angiogenesis and immune responses in the tumor
microenvironment. Truncation of the amino-terminal of
WRS generates cytokines that suppress angiogenesis [9].
YRS is cleaved into N- and C-terminal domains, which
have proangiogenic and immune activation functions,
respectively [10, 11]. One the other hand, 8 different
ARSs [bifunctional glutamyl-prolyl-tRNA synthetase
(EPRS), isoleucyl-tRNA synthetase (IRS), leucyl-tRNA
synthetase (LRS), glutaminyl-tRNA synthetase (QRS),
lysyl-tRNA synthetase (KRS), arginyl-tRNA synthetase
(RRS), aspartyl-tRNA synthetase (DRS), and methionyl
tRNA synthetase (MRS)] form a complex with ARS-
interacting multifunctional proteins (AIMPs) and play
noncanonical roles [8]. EPRS is a translational silen-
cer that suppresses vascular endothelial growth factor
A [12]. KRS binds to microphthalmia-associated tran-
scription factor (MITF) and is involved in the de-
velopment of melanoma [13]. QRS interacts with
apoptosis signal-regulating kinase 1 and suppresses
apoptosis in a glutamine-dependent manner [14].
These reports suggested that ARS overexpression
may impact cancer survival and progression and that
ARS inhibitors are thus potential anticancer thera-
peutics. In addition, the multifunctional nature of
ARSs and their localization to multiple areas suggest
their potential as cancer diagnostic biomarkers in
peripheral blood and tissue.
MRS is a critical enzyme in translation initiation and
transfers Met to the initiator tRNA (tRNAi
Met), sugges-
ting that this enzyme may play an important role in
tumor growth [15]. MRS increases ribosomal RNA bio-
genesis in the nucleolus and interacts with various
signaling molecules such as mTORC1, GCN2, CDK4,
and VEGFR [7, 16, 17]. After phosphorylation of MRS at
Ser662 by UV-mediated DNA damage, MRS dissociates
from AIMP3 and links the DNA damage responses to
global translation control [15]. For this reason, MRS has
been considered a strong biomarker candidate for the
therapy of lung cancer.
Here we evaluated MRS expression in mouse tissue
and in human lung cancer tissue to determine its clinical
implications. In addition, we evaluated the relationship
between MRS expression and the mTOR pathway, which
plays a critical role in cancer growth and proliferation,
to examine the relationship between tumor growth and
MRS expression.
Methods
Study design and subjects
Immunoblot and immunohistochemical (IHC) analyses
were performed using tissue lysates and paraffin-
embedded tissue blocks from the major organs of 8-week-
old wild type C57BL/6 mice. To evaluate MRS expression
in mouse lung cancer tissue, LSL-Kras G12D and LSL-
Kras G12D:p53fl/fl mice were sacrificed 24 and 8 weeks
after AdCre particle inhalation, respectively (https://nci-
frederick.cancer.gov/Lasp/MouseRepository/Default.aspx).
All animal work was approved by the Institutional Animal
Care and Use Committee of Yonsei University (2014–
0229-1) and followed the guidelines of the American
Association for the Assessment and Accreditation of
Laboratory Animal Care. To evaluate MRS expression in
human lung cancer, 12 paired lysates from adjacent nor-
mal appearing lung tissue and cancer enriched tissue
were analyzed by immunoblotting. Another set of 231
formalin-fixed paraffin embedded lung cancer tissue
slides were analyzed by IHC. This study was approved
by the IRB of Gangnam Severance Hospital (IRB #3–
2014-0299) and was carried out in compliance with
the Declaration of Helsinki (https://www.wma.net/pol-
icies-post/wma-declaration-of-helsinki-ethical-princi-
ples-for-medical-research-involving-human-subjects/#)
and Korean GCP guidelines.
Antibodies and immunoblotting
Anti-MRS and anti-LRS antibodies were purchased from
Neomix Inc. (Suwon, Gyeonggi-do, Korea); anti-Ki67
antibodies were obtained from Abcam (Cambridge, UK).
All other antibodies were obtained from Cell Signaling
Technology (Danver, MA, USA) unless otherwise stated.
Cells were harvested on ice and lysed in 2× Laemmli
sample buffer containing protease and phosphatase
inhibitors (GeneDepot, Barker, TX, USA). After soni-
cation, 30–50 μg of lysate was separated by gel elec-
trophoresis on 7.5 to 12% polyacrylamide gels and
transferred onto nitrocellulose membranes (Bio-Rad
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Laboratories, Richmond, CA, USA). The expression level
of each protein was quantified relative to that of β-actin.
IHC analysis
The expression of MRS, Ki67, pS6, and pGSK-3β in non-
small cell lung cancer (NSCLC) and mouse tissue samples
was analyzed by IHC using the LABS®2 System (Dako, Car-
pinteria, CA, USA) according to the manufacturer’s instruc-
tions. Briefly, sections were deparaffinized, rehydrated,
immersed in H2O2 methanol solution, and then incubated
overnight with primary antibodies against MRS, Ki67, pS6,
and pGSK-3β. Incubations were performed in antibody di-
luent (Dako) at dilutions of 1:500, 1:2000, 1:400, and 1:100,
respectively. Sections were incubated for 10 min with a bio-
tinylated linker and then processed using avidin/biotin IHC
techniques. 3,3′-Diaminobenzidine (DAB) was used as a
chromogen in conjunction with the Liquid DAB Substrate
kit (Novacastra, UK). MRS expression was scored as the
product of staining intensity and the percentage of posi-
tive cells. Staining intensity was classified as 0, 1, 2, or 3.
Frequency was classified as 0 (<10%), 1 (10–50%), 2(51–
80%), or 3 (>80%). Overexpression was defined as when
the product of intensity and frequency was ≥2.
Statistics
Clinically significant differences of MRS expression
levels were identified using the χ2 test, Fisher’s exact test,
and the independent 2 sample t-test. Disease free sur-
vival (DFS) was defined as the period from the time of
surgery to the time of recurrence and overall survival
(OS) was defined as the period from diagnosis to death.
Predictive factors for DFS and OS were calculated using
the Kaplan-Meier estimator and a Cox proportional
hazards model. All significance tests were 2-tailed and
P-values less than 0.05 were considered to indicate
statistical significance. All analyses were performed
using SPSS, version 20 (SPSS Inc., Chicago, IL, USA).
Results
MRS expression in various mouse tissues
To explore the potential of MRS as a therapeutic target
of lung cancer, we first evaluated MRS expression in the
non-neoplastic tissues of the major organs of 8-week-old
wild type C57BL/6 mice (Fig. 1 and Additional file 1).
Among the tested organs, MRS expression was highest
in the spleen and intestinal epithelium, whereas MRS
expression was weak in the kidney, liver, and lungs. Of
the cell types in the intestine, enterocytes in the intes-
tinal mucosal epithelium had strong cytoplasmic MRS
expression. Splenocytes in the center of the periarterial
lymphatic sheath did not express MRS, whereas those in
the periphery of the germinal center did. In the kidney,
the proximal convoluted tubule cells showed weak ex-
pression. With the exception of bronchial epithelial cells,
which had weak MRS expression, the majority of lung
cells did not express MRS. In the hepatic lobules, only
hepatocytes had weak cytoplasmic MRS expression.
MRS plays a critical role in the initial step of protein
synthesis and is also involved in signaling via its interac-
tions with mTORC1 and CDK4 [7, 16, 17]. Because MRS
also suggested to be involved in the cell cycle progression
via increasing stability of CDK4 (unpublished data)., we
next investigated whether MRS expression is related cell
proliferation (Fig. 1, Additional files 1 and 2 A-B) and/or
to mTOR activity (Fig. 1, Additional files 1 and 2 C-F)
[15]. Ki67 was strongly expressed in the spleen and intes-
tine, two organs exhibiting high MRS expression. The
kidney was an exception to this trend in that it did not
exhibit expression of MRS or mTOR markers, but did
show Ki67 expression. We performed IHC of renal tissue
to validate this finding and observed that Ki67 was occa-
sionally detected in the nuclei of proximal convoluted
tubule cells. To evaluate the relationship between MRS
expression and mTOR activity on the cellular level, the
expression levels of pS6 (Ser235/236) and pGSK-3β (Ser
9), surrogate markers of mTORC1 and mTORC2, respec-
tively, were evaluated in the same mouse tissue samples
by IHC. pS6 (Ser235/236) was strongly expressed in intes-
tinal and bronchial epithelial cells, with expression foci
also observed in splenocytes, renal tubular cells, and hepa-
tocytes. pGSK-3β (Ser 9), an mTORC2 marker, showed a
similar but weaker expression than that of pS6, indicating
that the expression patterns of mTOR surrogate markers
and MRS correspond with each other in these non-
neoplastic mouse tissues. To validate MRS expression in
the tested organs, we performed immunoblot analysis of
the tissue lysates and included a heart lysate as a control,
which was shown to have high MRS expression in pre-
vious experiments (Fig. 2a). Similar to the IHC results,
MRS expression intensity was highest in the spleen,
followed by the intestine and then the other organs.
MRS is frequently and specifically overexpressed in lung
cancer and is related to mTORC1 activity
To determine if MRS expression is specific to lung can-
cer, MRS expression was then evaluated in normal
appearing adjacent lung tissue (Fig. 2b). MRS was not
detected in alveolar type I and type II pneumocytes, nor
was it detected in the vascular structures. However,
MRS was weakly expressed in epithelial cells in the
bronchioles and bronchi. Lung cancer-specific MRS
overexpression was observed in Kras-LSL G12D and
Kras-LSL G12D:p53fl/fl murine lung cancer cells (Fig. 2c).
In this model, lung cancer is induced by AdCre inhalation.
Lung cancer-specific MRS overexpression was further
evaluated by immunoblot analysis of lysates from human
lung cancer and adjacent normal appearing lung tissue
(Table 1 and Fig. 2d). Of the 12 pairs of cancer and normal
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tissue lysates, 9 pairs (75%) showed clear overexpression
of MRS in the lung cancer tissue lysates. No pair exhibited
higher MRS expression in the normal appearing lung
tissue lysate compared with the cancer lysate.
To identify the molecules associated with MRS overex-
pression, we analyzed the expression of mTOR signaling
molecules (Fig. 2d). Among the ARSs tested, LRS showed a
similar expression pattern to MRS, although MRS was
more frequently detected than LRS. This finding is interest-
ing because LRS detects intracellular leucine and activates
mTORC1 signaling [7]. Interestingly, immunoblot analysis
of tumor tissue lysates revealed that MRS expression was
more closely associated with mTORC1, p70S6K, and pS6
expression as opposed to mTORC2 expression. To make
the relationship between MRS and mTOR1 signaling
clearer, serial sections from a number of human NSCLC
was immunostained and analyzed for their correlation
(Additional file 3). The expression of MRS showed a signifi-
cant positive correlation with expression of pS6, LRS, and
HSP70. These findings are consistent with the immunoblot
analyses of wild type mouse tissue lysates. Taken together,
our data indicate that MRS is frequently expressed and is
highly specific to NSCLC, suggesting that MRS is one of
potential candidate of therapeutic target of lung cancer.
MRS expression is related to poor prognosis in NSCLC
To further validate the clinical implications of MRS ex-
pression in lung cancer, we assessed MRS expression in
231 paraffin-embedded NSCLC tissue specimens. MRS
was mainly expressed in the cytoplasm of lung cancer
cells (Fig. 3a and b). MRS expression was scored as fol-
lows: product of intensity and frequency 0–1, negative/
trace expression; product of intensity and frequency
more than 2, positive MRS expression. A total of 179
(77.4%) NSCLC cases showed positive MRS cytoplasmic
expression. On the other hands, 73 (31.6%) cases showed
nuclear expression. The cytoplasmic MRS-positive ex-
pression rate in NSCLCs was comparable to the im-
munoblotting results.
To explore the clinical implications of MRS expression
in NSCLC, cases were classified into the following 2
groups according to cytoplasmic MRS expression status:
negative/trace (score 0–1) and positive expression (score
2–9). The clinical/pathological characteristics of the two
groups were then compared (Table 2). A total of 78
(33.8%) out of the 231 cases were female; the mean pa-
tient age was 61.6 ± 10.73 years. These parameters are
similar to the general characteristics of NSCLC. Among
the tested parameters, the proportion of MRS-positive
Fig. 1 Expression of MRS, Ki67, and, mTOR signaling proteins in the wild type mouse organs. The expression of MRS, Ki67, pS6 (Ser235/236), and
pGSK-3β (Ser9) was evaluated by IHC in tissue samples from 8-week-old wild type C57BL/6 mice. pS6 (Ser235/236) and pGSK-3β (Ser9) are surrogate
markers of mTORC1 and mTORC2 activity, respectively. IHC analysis revealed that the enterocytes in the intestinal mucosal epithelium and
the splenocytes in the periphery of the germinal center expressed MRS, whereas all other organs exhibited weak MRS expression. Photo
was taken at low power magnification (X100)
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cases gradually increased as the pStage increased
(p = 0.018, Pearson’s χ2-test). Age, sex, smoking history,
pathologic classification, and stage did not differ be-
tween the MRS expression groups.
To evaluate the effect of MRS expression on clinical
outcomes, disease-free survival (DFS) and overall sur-
vival (OS) of the groups were compared using Kaplan-
Myer estimators (Fig. 4). The median follow-up duration
was 121.4 months (95% CI; 100.34–142.46 months); 78
(32.1%) cases experienced lung cancer recurrence. A
total of 124 (51.0%) patients died during the follow-up
period. The MRS expression group showed poor clinical
outcomes, in particular significantly poor DFS (161.6 vs
142.3 months, P = 0.014, log-rank test). The OS curves
of the 2 groups were clearly separated, with the OS
curve of the MRS expression group shorter than that of
the other group; however, this trend did not reach statis-
tical significance.
To test the hypothesis that MRS overexpression is an
independent prognostic factor in NSCLC, univariate
and multivariate analyses were performed using a Cox
regression hazard model (Table 3). Univariate analysis
revealed that MRS expression and pStage were signi-
ficant predictors of poor DFS. Multivariate analysis in-
cluding MRS expression, age, sex, smoking status,
pStage, and pathology showed that pStage was the only
factor that significantly influenced DFS.
Discussion
Besides its canonical role as a translation initiator by
transferring Met to initiator tRNAi
Met, MRS has multiple
noncanonical functions. MRS senses intracellular Met,
a
d
b
c
Fig. 2 Expression of MRS, Ki67, and, mTOR signaling proteins in the wild type mouse organs (a) and MRS expression in lung cancer and normal
appearing adjacent lung tissue specimens (b-d). a Expression of MRS, mTOR signaling proteins, and Ki67 was evaluated by immunoblotting using
tissue lysates from 8-week-old wild type C57BL/6 mice. IHC of MRS expression in (b) human adjacent normal lung tissue and (c) LSL-Kras G12D
and LSL-Kras-G12D:p53fl/fl murine lung cancer tissue. d Immunoblot analysis of MRS expression and mTOR components in 12 pairs of lung cancer
and adjacent normal appearing lung tissue lysates
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leading to the activation of mTORC1 signaling [18], and
also stabilizes CDK4, thereby inducing cell cycle pro-
gression (unpublished data). MRS also detects intracellu-
lar oxidative stress, defends cells from DNA damage,
and controls protein synthesis [15]. In addition to these
roles, the discovery of MRS genetic variations in the
late-onset autosomal dominant Charcot–Marie–Tooth
neuropathy indicates that MRS has additional uncharac-
terized roles [19].
We evaluated MRS expression in the organs of wild
type C57BL/6 mice and observed only low levels of ex-
pression. Remarkably, MRS was strongly expressed in
heart tissue, whereas MRS expression was lower in hep-
atic tissues, where protein is more actively synthesized
a
b c
Fig. 3 Frequency and intensity of MRS expression in NSCLC tissue. a Representative images of cytoplasmic and nuclear MRS expression in NSCLC
tissue. Distribution of cytoplasmic (b) and nuclear (c) expression of MRS in 231 NSCLC cases as assessed by IHC. The expression score was calculated as
the product of the intensity and the frequency
Table 1 Clinical and pathological characteristics of the samples used for immunoblotting
Random No. Age range Cell type Differentiation Smoking TNM Stage
A39 70s Adeno n.s.a None smoker T3N0M0 IIB
A42 40s Adeno acinar type None smoker T1aN2M0 IIIA
A44 70s Adeno solid predominant Ex-smoker T2aN0M0 IB
A45 70s Adeno papillary predominant None smoker T1bN0M0 IA
A47 60s Squamous n.sa None smoker T2aN0M0 IB
A48 60s Squamous moderately differentiated Current smoker T2aN1M0 IIA
A49 60s Squamous poorly differentiated Ex-smoker T2aN0M0 IB
A50 60s Adeno micropapillary predominant pattern Ex-smoker T2aN1M0 IIA
A55 50s Adeno micropapillary predominant with extracellur mucin fomation Current smoker T2aN2M0 IIIA
A56 70s Adeno acinar predominant Current smoker T1bN2M0 IIIA
A57 60s Squamous moderately differentiated Ex-smoker T2bN2M0 IIIA
A63 70s Adeno acinar predominant None smoker T2aN0M0 IB
n.s.a: not specified
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than in the spleen and intestine. MRS expression was
weakly correlated with mTOR signaling components in
wild type mouse tissue samples; however, the correlation
between mTORC1 signaling and MRS overexpression
was more prominent in the NSCLC tissue samples.
These findings suggest that the regulatory mechanisms
are working properly in normal tissue, but that in cancer
tissue these mechanisms are dysregulated and the cancer
cells are dependent on mTOR signaling. However, more
evidence is required to prove that activation of the
mTOR pathway induces MRS overexpression.
The majority of the NSCLC tissue samples showed
clear expression of MRS, with cytoplasmic expression
more frequent than nuclear expression. Nuclear MRS
has unique functions in growth stimulating conditions
related to ribosomal RNA biosynthesis [20]. In this
study, a small percentage (31.6%) of NSCLC cells
showed nuclear MRS expression, which was not statisti-
cally significant. This finding might be due to the fact
that few cases exhibited nuclear MRS overexpression,
meaning that the sample size was too small to detect
significance.
When the Kaplan-Myer estimator was used to assess
the clinical implications of MRS expression, MRS ex-
pression was not found to be an independent prognostic
factor for DFS. This finding may be due to the positive
correlation between the degree of MRS expression and
the age of the study participant (Pearson correlation co-
efficient = 0.145, P = 0.027) and the strong relationship
between pStage and MRS expression. Evaluation of the
individual TNM staging components revealed that
maximal tumor diameter and T staging component were
associated with MRS expression. Moreover, MRS expres-
sion was significantly higher with each N stage incre-
ment (P = 0.007, Pearson’s χ2-test), suggesting that MRS
may play a role in lymphangitic metastasis. Using the
Table 2 Clinical and pathological characteristics of the patients
according to the expression of MRS
Expression of MRS P-value
Negative/Trace
(n = 52)
Positive
(n = 179)
Age (years) 61.1 ± 10.79 62.0 ± 10.71 0.613
Gender
Male 33 120 0.631
Female 19 59
Diameter (cm) 3.5 ± 1.96 3.7 ± 1.93 0.602
Smoking
status
None-smoker 22 63 0.762
Ex-smoker 11 38
Current smoker 15 63
Unknown 4 12
Pack Year 24.1 ± 25.40 25.1 ± 24.98 0.102
Pathology
Adenocarcinoma 31 99 0.597
Squamous
cancer
21 74
Othersa 0 6
PET-SUV 8.6 ± 4.41 9.1 ± 5.96 0.868
pStage
I 38 94 0.018
II 10 34
III 4 48
IV 0 2
aThese cases were composed of 2 large cell carcinomas, 2 atypical carcinoids,
1 mucoepidermoid carcinoma, and 1 pleomorphic carcinoma
a b
Fig. 4 Impact of cytoplasmic MRS expression on (a) DFS and (b) OS in 231 NSCLC cases. P-values were obtained by the log-rank test
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gene expression datasets of lung adenocarcinoma and
lung squamous cell carcinoma from the TCGA, the ef-
fect of MRS gene expression level on clinical outcome
was analyzed. In the lung cancer dataset that includes all
stages, there were no prominent differences in clinical
outcome according to MRS level, whereas in the sub-
group of stage III ~ IV the patients with elevated MRS
level tended to show a poor clinical outcome (Additional
file 4 A-C).
We anticipate that this initial confirmation of MRS ex-
pression in cancer tissue and demonstration of its clin-
ical implications will lead into future investigations of
the potential of MRS expression a therapeutic target for
drug development. To be developed as a diagnostic bio-
marker, MRS expression needs to be easily evaluated in
readily obtainable bodily fluid. Also, the mechanisms
driving MRS overexpression need to be elucidated. One
possible explanation of MRS overexpression is copy
number gain at the MRS gene locus (COSMIC); how-
ever, only limited cases showed copy number gain. In
order to develop MRS as a therapeutic target, a target-
able site also needs to be identified in MRS.
Conclusions
In conclusion, MRS is specifically and frequently overex-
pressed in NSCLC tissue. MRS overexpression in
NSCLC tissue was related to mTORC1 activity and poor
clinical outcomes, suggesting that further studies on
MRS overexpression are warranted to pursue MRS as a
therapeutic target.
Additional files
Additional file 1: Supporting data 1.pptx. Expression of MRS, Ki67, and,
mTOR signaling proteins in the wild type mouse organs. The expression
of MRS, Ki67, pS6 (Ser235/236), and pGSK-3β (Ser9) was evaluated by IHC
in tissue samples from 8-week-old wild type C57BL/6 mice. Photo was
taken at high power magnification (X1000). (PPTX 6359 kb)
Additional file 2: Supporting data 2.pptx Double immunofluorescent
staining of MRS with Ki67, and, mTOR signaling proteins in the wild type
mouse organs. The expression of MRS with Ki67 (A, B), pS6 (Ser235/236)
(C, D), and pGSK-3β (Ser9) (E, F) was evaluated by double immunofluorescent
staining in tissue samples from 8-week-old wild type C57BL/6 mice. (MRS:
red, others: green). Note that A, C, E was low power magnification (X 100)
and B, D, F are high power magnification (X 1000). (PPTX 41087 kb)
Additional file 3: Supporting data 3.pptx Expression of MRS and other
related proteins in human NSCLC (A) and their correlation Table (B). (A)
The expression of proteins was evaluated by IHC in tissue samples from
the same section. (B) Pearson correlation coefficient table relative to the
expression of MRS expression. P-value was obtained from bivariate
correlation analysis. (PPTX 2398 kb)
Additional file 4: Supporting data 4.pptx Survival analysis according
to the MRS level from TCGA NSCLC data set. Lung cancer cases of
(A) all stages, (B) stage I ~ II, and (C) and III ~ IV were selected from
lung adenocarcinoma and lung squamous cell carcinoma TCGA data
set and DFS and OS was evaluated according to the MRS level. The
expression of MRS was divided into two groups, upper 50% and lower
50%, based on the median value. P- values was obtained from Log-rank
test. (PPTX 892 kb)
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